Figure 1.

Predicted continuum of COVID-19 vaccine efficacy for patients with cancer based on cancer type and therapy

The majority of patients with cancer, including those who have solid tumors and are receiving active therapy, are expected to have protective titers following completion of COVID-19 vaccination. Specific patients with hematologic malignancies, such as cellular therapy recipients and those who are receiving B cell-depleting agents, may not mount protective responses. For a number of cancer types and regimens, vaccine-induced immune responses are unknown (right column) and warrant further research.

Abbreviations: ICI, immune checkpoint inhibitor; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; JAK, janus kinase.

^∗B cell-depleting agents include anti-CD20 agents (e.g., rituximab), anti-CD38 therapy, BCMA targeted agents, and Bruton tyrosine kinase inhibitors.